Form 4: Merck & Co. Director Mary Ellen Coe Reports Acquisition of Phantom Stock Units

Mary Ellen Coe, a director at Merck & Co., Inc., reported the acquisition of phantom stock units settled in cash, according to a Form 4 filing with the SEC.

Summary

• On December 31, 2024, Mary Ellen Coe, a director of Merck & Co., Inc., acquired phantom stock units.
• The phantom stock units are to be settled 100% in cash upon the reporting person's termination of service, according to a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.
• The transaction involved 301.5682 phantom stock units, each convertible to one share of common stock.
• The price of the derivative security was $99.48.
• Following the reported transaction, Ms. Coe beneficially owns 24,041.0793 derivative securities.
• Holdings include shares acquired in dividend reinvestment transactions.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects a director's increased stake in the company, suggesting confidence in its future performance. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's outlook.

Positives

• The acquisition of phantom stock units indicates confidence in the company's future performance.

Future Outlook

The phantom stock units will be settled in cash upon the reporting person's termination of service, according to a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.

Industry Context

This filing is a routine disclosure of a director's holdings in the company, which is common in the pharmaceutical industry. It provides transparency into the alignment of interests between management and shareholders.

Stakeholder Impact

• The acquisition of phantom stock units by a director can positively influence shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates